OncoNano Medicine
John Dyett is on the Board of Directors of OncoNano Medicine. He is also the Co-Founder and Managing Director of
Salem Partners, LLC.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
OncoNano Medicine
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple, and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents.